Hypersomnia, Narcolepsy
Conditions
Keywords
Sleep, real driving, simulated driving, MWT
Brief summary
The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting treatments on driving risks. It will reinforce the links between different research environments (sleep physiopathology, clinical research, cognitive neurosciences, driver's supervision, virtual reality, pharmacology) among the RESAT network (Réseau Eveil Sommeil Attention Transport). It will stimulate data acquisition in technological research to better understand the difference between real and simulated driving
Detailed description
Excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck accidents on French Freeways. Since the publication of a new law (arrêté du 28 décembre 2005 du journal officiel) regulating fitness to drive, the Maintenance of Wakefulness Test (MWT) is now mandatory to evaluate driving skills of patients suffering of excessive daytime sleepiness. The MWT has shown a good predictability of driving handicap on simulators in patients suffering from obstructive sleep apnea syndrome. Nevertheless no study has proven yet the predictability of the MWT regarding real and simulated driving in narcoleptics and hypersomniacs. Furthermore, even if alerting drugs significantly improve MWT scores there is no data available concerning the impact of these drugs on fitness to drive. This lack of knowledge is a major handicap to evaluate driving skills of treated patients suffering from excessive daytime sleepiness. The main objective of our project is to test the predictive value of the MWT on real and simulated driving performances in untreated and treated sleepy patients suffering from narcolepsy and hypersomnia. Inclusion of healthy volunteers will allow to collect reference data about somnolence during MWT.
Interventions
DRUGPlacebo
Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch): * during 3 days at home * during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
DRUGModafinil
Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch): * during 3 days at home * during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil).
Sponsors
University Hospital, Bordeaux
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
for Patients: * Narcoleptic patients with or without cataplexy or hypersomniacs * aged from 18 to 65 years, * treated for attacks of cataplexy, * treated with a maximum dose of Modiodal: 400 mg per day (4 tablets of 100mg), * without any other disease which could be responsible of excessive daytime sleepiness, * having their driver's licence, * driving more than 5000 Km/year, * registered to French national health and pensions organization, * having regular timetables of life 7 days before beginning the study, * having given their written light agreement in order to participate in the study. Inclusion Criteria for Healthy Volunteers: * without any sleep disorders, * having their driver's licence since at least 2 years, * driving more than 5000 Km/year, * registered to French national health and pensions organization, * having regular timetables of life 7 days before beginning the study, * having given their written light agreement in order to participate in the study.
Exclusion criteria
for Patients: * Night workers, * breast-feeding or pregnant women * Beck's scale score \< 8, * neurologic disease, * cardiovascular disorders including cardiac arrhythmia, * sleep disorders except narcolepsy and hypersomnia, * pulmonary disorders, * renal disorders, * endocrinal disorders, * having participated in a clinical study during the last 6 months, * unable to drive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep latency during MWT, number of vehicle's line crossing on the road, standard deviation of the vehicle's position on the road | for each condition, at day 4 for patients or day 1 for healthy volonteers |
Secondary
| Measure | Time frame |
|---|---|
| Subjective sleepiness (Karolinska and VAS scales) | for each condition, at day 4 and 5 for patients or day 1 for healthy volonteers |
| nocturnal sleep quality and quantity will be measured by PSG and Actimetry. | For each condition, at day 4 and 5 for patients or day 1 for healthy volonteers |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORPierre PHILIP, MD, PHD
University Hospital, Bordeaux
Outcome results
None listed